{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:41:35Z","timestamp":1791240095830,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Merck Research Laboratories"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.cbpa.2016.03.001","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T00:45:30Z","timestamp":1458261930000},"page":"34-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine"],"prefix":"10.1016","volume":"32","author":[{"given":"Janine T","family":"Bryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Buckland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin U","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2016.03.001_bib0450","series-title":"Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases","year":"2015"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0455","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"issue":"Suppl 5","key":"10.1016\/j.cbpa.2016.03.001_bib0460","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Formana","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0465","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0042-6822(91)90772-4","article-title":"Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles","volume":"185","author":"Zhou","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0470","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0475","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/jvi.67.4.1936-1944.1993","article-title":"Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of virus-like particles","volume":"67","author":"Rose","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0480","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/jvi.67.1.315-322.1993","article-title":"Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins","volume":"67","author":"Hagensee","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0485","first-page":"285","article-title":"Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003\u20132010","volume":"208","author":"Markowitz","year":"2013","journal-title":"JID"},{"key":"10.1016\/j.cbpa.2016.03.001_sbref0490","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 12","key":"10.1016\/j.cbpa.2016.03.001_bib0495","doi-asserted-by":"crossref","first-page":"M80","DOI":"10.1016\/j.vaccine.2008.05.041","article-title":"Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention","volume":"26","author":"Garland","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0500","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CVI.00591-14","article-title":"Efficacy of human papillomavirus 16 and 18 (HPV-16\/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial","volume":"22","author":"Apter","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0505","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1357-4310(00)01685-3","article-title":"Cervical cancer risk: is there a genetic component?","volume":"6","author":"Magnusson","year":"2000","journal-title":"Mol Med Today"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0510","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ijc.2910250509","article-title":"Partial characterization of viral DNA from human genital warts (Condylomata acuminata)","volume":"25","author":"Gissmann","year":"1980","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0515","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1128\/jvi.40.3.932-935.1981","article-title":"Molecular cloning of viral DNA from human genital warts","volume":"40","author":"de Villiers","year":"1981","journal-title":"J Virol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0520","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0525","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1128\/JCM.00235-10","article-title":"Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection","volume":"49","author":"Roberts","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0530","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/JCM.00236-10","article-title":"Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPVgenotyping extra assay","volume":"49","author":"Else","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0535","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0540","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jnci\/87.11.779","article-title":"Cancer causes revisited: human papillomavirus and cervical neoplasia","volume":"87","author":"Franco","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0545","series-title":"Fields Virology","year":"2001"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0550","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/317639a0","article-title":"Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminate","volume":"317","author":"Kreider","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0555","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ijc.2910390409","article-title":"Susceptibility of various human tissues to transformation in vivo with human papillomavirus type 11","volume":"39","author":"Kreider","year":"1987","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0560","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1128\/jvi.69.6.3959-3963.1995","article-title":"Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection","volume":"69","author":"Breitburd","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0565","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1073\/pnas.92.25.11553","article-title":"Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas","volume":"92","author":"Suzich","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0570","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/0264-410X(95)00103-8","article-title":"Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation","volume":"13","author":"Jansen","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0575","series-title":"Hepatitis B Vaccines in Clinical Practice","first-page":"159","article-title":"Scope and design of hepatitis B vaccine clinical trials","author":"West","year":"1993"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0580","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/jnci\/92.5.397","article-title":"Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial","volume":"92","author":"ALTS Group","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0585","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479","article-title":"Chapter 1: Human papillomavirus and cervical cancer\u2014burden and assessment of causality","author":"Bosch","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0590","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/jnci\/87.11.796","article-title":"Prevalence of human papillomavirus in cervical cancer: a worldwide perspective","volume":"87","author":"Bosch","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0595","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0600","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1006\/viro.1995.1283","article-title":"Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae","volume":"209","author":"Hofmann","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0605","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1099\/0022-1317-77-3-465","article-title":"Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae","volume":"77","author":"Hofmann","year":"1996","journal-title":"J Gen Virol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(96)00388-5","article-title":"Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisiae","volume":"180","author":"Neeper","year":"1996","journal-title":"Gene"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0615","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/prep.1999.1155","article-title":"Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae","volume":"17","author":"Cook","year":"1999","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0620","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1042\/BA20060240","article-title":"An automated microscale chromatographic purification of virus-like particles as a strategy for process development","volume":"47","author":"Wenger","year":"2007","journal-title":"Biotechnol Appl Biochem"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0625","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/bit.24493","article-title":"Vaccine process technology","volume":"109","author":"Josefsberg","year":"2012","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0630","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/jps.20696","article-title":"Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs)","volume":"95","author":"Mach","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0635","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.nano.2012.01.007","article-title":"Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles","volume":"8","author":"Zhao","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0640","doi-asserted-by":"crossref","first-page":"734","DOI":"10.4161\/hv.27316","article-title":"Characterization of virus-like particles in GARDASIL\u00ae by cryo transmission electron microscopy","volume":"10","author":"Zhao","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0645","unstructured":"Zhao Q, Wu S, Manger W, Gadam S: Process for making human papillomavirus virus-like particles with improved properties. US Patent 6,436,402, 2002."},{"key":"10.1016\/j.cbpa.2016.03.001_bib0650","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.clpt.6100055","article-title":"GARDASIL: Prophylactic human papillomavirus vaccine development-from bench top to bed-side","volume":"81","author":"Shi","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0655","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1743-422X-9-52","article-title":"Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity","volume":"9","author":"Zhao","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0660","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4161\/hv.2.4.2989","article-title":"Evaluation of the thermal stability of Gardasil","volume":"2","author":"Shank-Retzlaff","year":"2006","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0665","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1038\/nm1218","article-title":"The process development challenge for a new vaccine","volume":"11","author":"Buckland","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.cbpa.2016.03.001_sbref0670","series-title":"Vaccine Analysis: Strategies, Principles, and Control","article-title":"Recombinant virus-like particle protein vaccines","author":"Sitrin","year":"2015"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0675","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4161\/hv.3.4.4309","article-title":"Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice","volume":"3","author":"Caulfield","year":"2007","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0680","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4161\/hv.1.5.2126","article-title":"Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples","volume":"1","author":"Shank-Retzlaff","year":"2005","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0685","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/(SICI)1096-9071(199711)53:3<185::AID-JMV1>3.0.CO;2-4","article-title":"Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration","volume":"53","author":"Bryan","year":"1997","journal-title":"J Med Virol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0690","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4161\/hv.4.2.5261","article-title":"Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11","volume":"4","author":"Smith","year":"2008","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0695","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.vaccine.2003.11.059","article-title":"Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine","volume":"22","author":"Brown","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0700","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jcv.2006.03.013","article-title":"Detection of HPV in Norwegian cervical biopsy specimens with type-specific PCR and reverse line blot assays","volume":"36","author":"Roberts","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0705","unstructured":"Jansen K, Taddeo F, Li W, DiCello A: Fluorescent multiplex HPV PCR assays using multiple fluorophores. US Patent publication number: 20050175987."},{"key":"10.1016\/j.cbpa.2016.03.001_bib0710","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/jmv.20512","article-title":"Detection of specific human papillomavirus types in paraffin-embedded sections of cervical carcinomas","volume":"78","author":"Bryan","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0715","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/jmv.21561","article-title":"Importance of specimen type in detecting human papillomavirus DNA from the female genital tract","volume":"81","author":"Roberts","year":"2009","journal-title":"J Med Virol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0720","first-page":"1186","article-title":"Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titers","volume":"284","author":"Brown","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0725","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1016\/j.vaccine.2003.11.058","article-title":"Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particles candidate vaccines in young healthy women","volume":"22","author":"Fife","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0730","doi-asserted-by":"crossref","first-page":"601","DOI":"10.4065\/80.5.601","article-title":"Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial","volume":"80","author":"Poland","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0735","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0740","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0745","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/647993","article-title":"Human papillomavirus (HPV) type 16 and type 18 DNA loads at baseline and persistence of type-specific infection during a 2-year follow-up","volume":"200","author":"Xi","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0750","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0755","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer SK1","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0760","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"Dillner","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0765","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0770","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cbpa.2016.03.001_sbref0775","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/CVI.00133-15","article-title":"Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine","volume":"22","author":"Nyg\u00e5rd","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0780","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/ijc.25940","article-title":"Impact of an HPV6\/11\/16\/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16\/18 infection","volume":"129","author":"Haupt","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0785","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/OLQ.0b013e3181ad25ff","article-title":"Prevalence and incidence of HPV genital infection in women","volume":"36","author":"Velicer","year":"2009","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0790","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0795","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24\u201345 years: a randomised, double-blind trial","volume":"373","author":"Mu\u00f1oz","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0800","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0805","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.bjc.6601024","article-title":"Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis","volume":"89","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0810","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","article-title":"Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis","volume":"88","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0815","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/1097-0061(20000915)16:12<1131::AID-YEA609>3.0.CO;2-F","article-title":"Relationship of codon bias to mRNA concentration and protein length in Saccharomyces cerevisiae","volume":"16","author":"Coghlan","year":"2000","journal-title":"Yeast"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0820","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/(SICI)1097-0061(19990615)15:8<633::AID-YEA407>3.0.CO;2-O","article-title":"The positive relationship between codon usage bias and translation initiation AUG context in Saccharomyces cerevisiae","volume":"15","author":"Miyasaka","year":"1999","journal-title":"Yeast"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0825","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/j.1365-2958.1996.tb02468.x","article-title":"mRNA sequences influencing translation and the selection of AUG initiator codons in the yeast Saccharomyces cerevisiae","volume":"19","author":"Yun","year":"1996","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0830","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.1093\/nar\/20.20.5289","article-title":"Evolution of codon usage patterns: the extent and nature of divergence between Candida albicans and Saccharomyces cerevisiae","volume":"20","author":"Lloyd","year":"1992","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0835","unstructured":"Jansen J, Schultz L, Neeper M, Markus H: Codon-optimized papilloma virus sequences. US Patent Publication number: 20060177817, 2006."},{"key":"10.1016\/j.cbpa.2016.03.001_bib0840","unstructured":"Bryan J, Brownlow M, Schultz L, Wang XM, Jansen K: Optimized expression of HPV 58 l1 in yeast. US Patent 7976848, Publication number: 20070036824, 2007."},{"key":"10.1016\/j.cbpa.2016.03.001_bib0845","unstructured":"Bryan J, Brownlow M, Schultz L, Jansen K: Optimized expression of HPV 45 l1 in yeast. US Patent 7482015, Publication number: 20060240040, 2006."},{"key":"10.1016\/j.cbpa.2016.03.001_bib0850","unstructured":"Bryan J, Brownlow M, Schultz L, Jansen K: Optimized expression of HPV 52 L1 in yeast. US Patent 7744892, Publication number: 20100035818, 2010."},{"key":"10.1016\/j.cbpa.2016.03.001_sbref0855","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cbpa.2016.03.001_sbref0860","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/21645515.2015.1012010","article-title":"Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine","volume":"11","author":"Luxembourg","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0865","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0870","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1002\/eji.200737820","article-title":"Prevention of cancer through immunization: prospects and challenges for the 21st century","volume":"37","author":"Frazer","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0875","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-immunol-031210-101308","article-title":"Prevention and treatment of papillomavirus-related cancers through immunization","volume":"29","author":"Frazer","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0880","doi-asserted-by":"crossref","first-page":"e99114","DOI":"10.1371\/journal.pone.0099114","article-title":"Recurrent respiratory papillomatosis: HPV genotypes and risk of high-grade laryngeal neoplasia","volume":"9","author":"Omland","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0885","article-title":"Oropharyngeal cancer and human papilloma virus: evolving diagnostic and management paradigms","volume":"7","author":"Buckley","year":"2015","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.cbpa.2016.03.001_bib0890","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijporl.2014.11.022","article-title":"Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: successful treatment with the quadrivalent human papillomatosis vaccine","volume":"79","author":"M\u00e9szner","year":"2015","journal-title":"Int J Pediatr Otorhinolaryngol"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136759311630014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136759311630014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:36:10Z","timestamp":1761273370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S136759311630014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":89,"alternative-id":["S136759311630014X"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2016.03.001","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2016.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}